Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2012 4
2014 1
2015 2
2016 1
2017 1
2018 1
2019 5
2020 8
2021 6
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Palumbo G, Farruggia P, Ramenghi U, Russo G, Borchiellini A, Spinelli M, Dufour C, Giona F, Ladogana S, Zecca M, Perrotta S, Pession A, Giordano P. Palumbo G, et al. Among authors: borchiellini a. Hematology. 2023 Dec;28(1):2210906. doi: 10.1080/16078454.2023.2210906. Hematology. 2023. PMID: 37199369
Use of the von Willebrand factor concentrate with low factor VIII content to manage patients with inherited von Willebrand disease requiring surgical or secondary long-term prophylaxis: An expert opinion paper from an Italian panel.
Castaman G, Borchiellini A, Coppola A, Cultrera D, Marino R, Federici AB, Giuffrida AC, Marchesini E, Molinari AC, Maria SS, Zanon E. Castaman G, et al. Among authors: borchiellini a. Eur J Haematol. 2022 Aug;109(2):121-128. doi: 10.1111/ejh.13785. Epub 2022 May 24. Eur J Haematol. 2022. PMID: 35531770 Review.
Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa.
Novembrino C, Quaglia I, Molinari AC, Borchiellini A, Coppola A, Santoro RC, Boscolo-Anzoletti M, Galbiati E, Zanon E, Valpreda A. Novembrino C, et al. Among authors: borchiellini a. Diagnostics (Basel). 2022 Aug 18;12(8):1999. doi: 10.3390/diagnostics12081999. Diagnostics (Basel). 2022. PMID: 36010349 Free PMC article.
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, Rivolta GF, Santoro C, Zanon E, Sciacovelli L, Manca S, Lubrano R, Golato M, Tripodi A, Rocino A; ad hoc Working Group. Coppola A, et al. Haemophilia. 2020 Nov;26(6):937-945. doi: 10.1111/hae.14172. Epub 2020 Oct 23. Haemophilia. 2020. PMID: 33094880 Review.
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Palandri F, Rossi E, Bartoletti D, Ferretti A, Ruggeri M, Lucchini E, Carrai V, Barcellini W, Patriarca A, Rivolti E, Consoli U, Cantoni S, Oliva EN, Chiurazzi F, Caocci G, Giuffrida G, Borchiellini A, Auteri G, Baldacci E, Carli G, Nicolosi D, Sutto E, Carpenedo M, Cavo M, Mazzucconi MG, Zaja F, De Stefano V, Rodeghiero F, Vianelli N. Palandri F, et al. Among authors: borchiellini a. Blood. 2021 Aug 19;138(7):571-583. doi: 10.1182/blood.2021010735. Blood. 2021. PMID: 33889952 Free article. Clinical Trial.
42 results